Glaxo Avoids Market for Lemons by Buying Collaborators
09:11 EDT 28 May 2012 | Current Partnering
GlaxoSmithKline may find its next acquisition target where the U.K. drugmaker found the last two: among more than a dozen companies it collaborates with to develop new treatments. Glaxo has stakes in more than 10 publicly-traded companies, including DiaDexus, which develops diagnostics for detecting heart attack and stroke risk, according to data compiled by Bloomberg. [...
Original Article: Glaxo Avoids Market for Lemons by Buying Collaborators
More From BioPortfolio on "Glaxo Avoids Market for Lemons by Buying Collaborators"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
